



AstraZeneca Pharma India Limited

Regd. Office : 'Avishkar' Off Bellary Road, Hebbal, Bangalore 560 024

Financial Results For The Quarter And Nine Months Ended 30 September 2009

Rs in lakhs (except for number of shares)

Sl No.	Particulars	3 months ended 30.09.2009 (Unaudited)	3 months ended 30.09.2008 (Unaudited)	9 months ended 30.09.2009 (Unaudited)	9 months ended 30.09.2008 (Unaudited)	Previous accounting year ended 31.12.2008 (Audited)
1	(a) Net sales (net of excise duty)	9,737.48	8,821.80	27,067.23	24,609.84	33,976.85
	(b) Other operating income:					
	- Service income	356.49	224.07	972.13	1,115.59	1,449.62
2	Expenditure					
	(a) (Increase) / decrease in stock-in-trade and work-in-progress	174.31	(625.85)	80.47	(915.49)	(931.77)
	(b) Consumption of raw materials and packing materials	1,489.21	1,272.01	3,244.06	3,267.49	4,296.86
	(c) Purchase of traded goods	1,485.53	1,810.84	5,288.13	4,658.89	6,585.62
	(d) Employees cost	2,209.60	1,576.86	6,454.35	4,657.71	6,217.28
	(e) Depreciation	153.21	194.21	451.29	489.67	687.63
	(f) Other expenditure	2,764.66	2,074.60	7,478.08	6,113.81	8,034.52
	(g) Total	8,276.52	6,302.67	22,996.38	18,272.08	24,890.14
3	Profit from operations before other income, interest & exceptional items (1-2)	1,817.45	2,743.20	5,042.98	7,453.35	10,536.33
4	Other income	69.54	283.24	458.04	817.86	1,387.57
5	Profit before interest & exceptional items (3+4)	1,886.99	3,006.44	5,501.02	8,271.21	11,923.90
6	Interest	-	126.02	13.70	360.27	486.30
7	Profit after interest but before exceptional items (5-6)	1,886.99	2,880.42	5,487.32	7,910.94	11,437.60
8	Exceptional items	-	-	-	-	-
9	Profit from ordinary activities before tax (7+8)	1,886.99	2,880.42	5,487.32	7,910.94	11,437.60
10	Tax expense	589.75	1,033.69	1,934.20	2,819.12	4,054.08
11	Net profit from ordinary activities after tax (9-10)	1,297.24	1,846.73	3,553.12	5,091.82	7,383.52
12	Extraordinary item	-	-	-	-	-
13	Net profit for the period (11-12)	1,297.24	1,846.73	3,553.12	5,091.82	7,383.52
14	Paid-up equity share capital (Face value of Rs 2 per equity share)	500.00	500.00	500.00	500.00	500.00
15	Reserves excluding revaluation reserves as per the balance sheet of previous accounting year					11,114.97
16	Basic and diluted earnings (Rs) per share (not annualised)	5.19	7.39	14.21	20.37	29.53
17	Public shareholding					
	- Number of shares	2,500,050	2,500,050	2,500,050	2,500,050	2,500,050
	- Percentage of shareholding	10.0002%	10.0002%	10.0002%	10.0002%	10.0002%
18	Promoters and promoter group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	-	-	-	-	-
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	-	-	-	-	-
	- Percentage of shares (as a % of the total share capital of the Company)	-	-	-	-	-
	b) Non-encumbered					
	- Number of shares	22,499,950		22,499,950		
	- Percentage of shares (as a % of the total shareholding of promoter and promoter group)	100%		100%		
	- Percentage of shares (as a % of the total share capital of the Company)	89.9998%		89.9998%		

Notes:

- The above statement of financial results was reviewed by the Audit Committee and having been recommended for approval, was approved by the Board of Directors of the Company at their meeting held on 27 October 2009.
- The Company has embarked on a long term growth strategy to significantly enhance its market presence by launch of new products to expand its product portfolio, coupled with consequential expansion of its field force. Towards this strategy the Company has made considerable investments in expanding its field force in the first half of FY 2009, which has resulted in increased manpower costs. This in turn has impacted the profitability for the current period as compared to the corresponding period of FY 2008.
- Status of investor complaints: a) Pending as on 1 July 2009 - NIL b) Received during the quarter - 8 c) Disposed off during the quarter - 8 d) Pending as on 30 September 2009 - NIL.
- The Board of Directors, at their meeting held on 12 January 2008, pursuant to the scheme of arrangement sanctioned by the Honourable High Court of Karnataka on 7 July 2007 and subsequent approval accorded by the Reserve Bank of India on 11 December 2007, allotted 8% secured fully paid-up redeemable non-convertible bonus debentures from the general reserve, in the ratio of one debenture of the face value of Rs 25 each for every equity share held by the shareholders of the Company as on 11 January 2008. The bonus debentures were listed on the Bangalore Stock Exchange Limited, Bombay Stock Exchange Limited and National Stock Exchange of India Limited. The bonus debentures and the interest thereon were redeemed on 11 January 2009.
- Comparative information for promoter and promoter group shareholding has not been disclosed as the disclosure requirements are effective from quarter ended 31 March 2009.
- Previous period figures have been regrouped/reclassified, wherever necessary to conform to the current period's presentation.

Segment wise revenue, results and capital employed

Rs in lakhs

Sl No.	Particulars	3 months ended 30.09.2009 (Unaudited)	Corresponding 3 months ended in the previous year 30.09.2008 (Unaudited)	9 months ended 30.09.2009 (Unaudited)	Corresponding 9 months ended in the previous year 30.09.2008 (Unaudited)	Previous accounting year ended 31.12.2008 (Audited)
1	Segment Revenue					
	(a) Healthcare	9,751.97	8,821.33	27,094.76	24,636.43	34,133.87
	(b) Clinical Trials Service	356.49	224.07	972.13	1,115.59	1,449.62
	Total	10,108.46	9,045.40	28,066.89	25,752.02	35,583.49
	Less: Inter-segment Revenue	-	-	-	-	-
	Net Income From Operations	10,108.46	9,045.40	28,066.89	25,752.02	35,583.49
2	Segment Results					
	Profit before Tax and Interest					
	(a) Healthcare	1,823.58	2,739.22	5,052.73	7,471.74	10,681.03
	(b) Clinical Trials Service	8.36	3.51	17.78	8.20	12.32
	Total	1,831.94	2,742.73	5,070.51	7,479.94	10,693.35
	Add: Other Income	55.05	283.71	430.51	791.27	1,230.55
	Less: Interest	-	126.02	13.70	360.27	486.30
	Total Profit Before Tax	1,886.99	2,880.42	5,487.32	7,910.94	11,437.60
3	Capital Employed					
	(a) Healthcare	9,413.01	8,327.56	9,413.01	8,327.56	8,816.80
	(b) Clinical Trials Service	(481.82)	(301.92)	(481.82)	(301.92)	(360.29)
	(c) Unallocated	6,236.91	5,684.95	6,236.91	5,684.95	3,158.46
	Total	15,168.10	13,710.59	15,168.10	13,710.59	11,614.97

Note: Certain assets and liabilities of the Healthcare segment are interchangeably used for Clinical Trials Service segment for limited purposes. Identification of such assets and liabilities is not feasible. Hence, such assets have not been allocated to any segment.

By Order of the Board of Directors
For AstraZeneca Pharma India Limited

Place : Bangalore
Dated : 27 October 2009

Anandh Balasundaram
Managing Director